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Abstract
BACKGROUND & AIMS—Oral sodium phosphate (OSP) is a common bowel purgative 
administered before colonoscopy; the Food and Drug Administration has warned against its use 
because of concerns about acute kidney injury (AKI) from the absorbed phosphate and dystrophic 
calcification. However, it is not clear if OSP is associated with AKI in the general population or in 
high-risk subgroups undergoing colonoscopy. We estimated the risk of AKI among patients 
undergoing a screening colonoscopy using OSP vs polyethylene glycol (PEG) for bowel cleansing 
in a large, US-based claims database.
METHODS—We used an insurance database to identify a cohort of patients ages 50 to 75 years 
who underwent screening colonoscopies as outpatients from January 2000 through November 
2008 (before the Food and Drug Administration warning), receiving OSP (n [ 121,266) or PEG (n 
[ 429,430) within 30 days beforehand, without prior use of either drug. We collected data from 
patients for 6 months afterward to identify those who developed AKI or renal failure, or received 
dialysis. Adjusted and propensity score-matched hazard ratios (HR) and 95% confidence intervals 
(CI) were estimated using Cox proportional hazards models. We investigated the effects in 
subgroups with higher AKI risk (patients with chronic kidney disease, kidney stones, 
hypertension, or diabetes, or using antihypertensive or nonsteroidal anti-inflammatory drugs).
RESULTS—AKI occurred in 0.2% of OSP users and in 0.3% of PEG users (adjusted HR, 0.86; 
95% CI, 0.75–0.99). OSP users matched well with PEG users, producing similar estimates (HR, 
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0.85; 95% CI, 0.72–1.01). We did not observe a consistent increase in the risk of AKI or other 
outcomes in any subgroups analyzed.
CONCLUSIONS—In a large database analysis, we did not associate administration of OSP 
before colonoscopy with increased risk of postprocedure AKI, even in high-risk clinical 
subgroups.
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Sodium phosphate preparations are effective agents for preprocedure bowel cleansing, 
although they may increase the risk of acute kidney injury (AKI). Healthy volunteers given 
oral sodium phosphate (OSP) solution showed enteric absorption of 50% of the phosphorus, 
an abrupt increase in serum phosphate concentration, and renal excretion of approximately 
14% of the absorbed load.1 Retained phosphate may have systemic consequences because it 
binds and precipitates with calcium,2–4 leading to dystrophic soft-tissue deposition in 
various organ systems. Kidney biopsy series have detailed calcium phosphate deposition in 
the distal tubule and collecting duct of patients with AKI after sodium phosphate use.5–9 
Observed cases of phosphate renal injury led the Food and Drug Administration (FDA) to 
place warnings of kidney injury on all over-the-counter and prescription sodium phosphate 
products used for bowel cleansing, including multicomponent preparation kits and 
prescription OSP tablets. The over-the-counter kits now contain reduced phosphate content 
and are marketed for treatment of constipation rather than precolonoscopy bowel cleansing. 
Most published case series have focused on multicomponent sodium phosphate preparation 
kits, although the FDA warning additionally was extended to OSP tablets. Although biopsy-
confirmed renal injury from OSP has been observed in individuals, it is unclear how these 
individual-level effects translate to population-level risks. Without the context of appropriate 
population denominators, the relative burden of OSP-induced AKI compared with other 
agents is unknown.
The available epidemiologic data from large populations are inconclusive regarding the risk 
of AKI after OSP use in large populations,10 with roughly half of the studies suggesting 
increased risk,11–14 and the remainder suggesting no risk.15–19 A major limitation of all of 
these studies was inadequate power given the relatively small numbers of participants, 
compounded by the low frequency of AKI events. In addition, these studies may be subject 
to confounding by indication, include both inpatient and outpatient colonoscopies, and rely 
on poorly defined or inappropriate comparison groups. The single randomized study20 
comparing OSP with polyethylene glycol (PEG), another commonly used bowel preparation 
agent, was funded by a maker of OSP and showed no difference in renal injury, but it also 
was limited by low power. The FDA warning on OSP notes that patients undergoing 
precolonoscopy bowel cleansing are at risk for dehydration, and it is possible that the 
observed AKI in OSP users may have resulted from inadequate rehydration rather than from 
the OSP directly.21 Given that OSP may be a more effective and less expensive 
purgative,22–26 quantifying the comparative risk of renal injury after its use may lead to 
more informed clinical decision making.
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We conducted a large retrospective cohort study of middle-aged and older adults undergoing 
an outpatient colonoscopy from 2000 to 2008 to determine the risk of AKI associated with 
OSP tablet exposure compared with PEG. We examined the risk of AKI among all 
participants as well as among high-AKI-risk subgroups, including those with alterations in 
renal calcium metabolism, which potentially can increase the risk from high-phosphate 
products.
Methods
We conducted a cohort study using a large, US-based administrative claims database. All 
analyses were performed with SAS 9.2 (SAS Institute, Inc, Cary, NC). This secondary 
analysis of de-identified administrative claims data was exempt from further review by the 
University of North Carolina at Chapel Hill Institutional Review Board.
Data Source
We used Truven MarketScan database (Truven Health Analytics Inc, Ann Arbor, MI), which 
is composed of 2 portions: (1) Commercial Claims and Encounters, employer-based 
commercial insurance plans for employees, spouses and dependents aged younger than 65 
years from large insurers throughout the United States; and (2) Medicare Supplementary and 
Coordination of Benefit, employer-based Medicare supplementary insurance for individuals 
aged 65 years or older. These databases contain enrollment information, inpatient and 
outpatient diagnosis and procedure claims, and pharmacy dispensing information. 
Participants have unique identifiers that permit longitudinal follow-up evaluation through 
linkage of claims.
Study Population
We identified individuals aged 50 to 75 years undergoing an outpatient screening 
colonoscopy between January 1, 2000, and November 11, 2008—1 month before the FDA 
warning to avoid channeling of high-risk AKI patients away from OSP—using Current 
Procedural Terminology codes (4523, 45355, 45378, 45379, 45380, 45381, 45382, 45384, 
45385, 45386, 45387, 45391, 45392, G0105, and G0121). We required at least 1 year of 
continuous enrollment before colonoscopy. If a patient had multiple eligible colonoscopies, 
only the first was considered. Individuals with AKI, end-stage renal disease, unspecified 
renal failure, rhabdomyolysis, dialysis, or renal transplantation in the baseline year before 
colonoscopy were excluded. To ensure utilization of the observed insurance plan for 
pharmacy benefits, patients were required to fill at least one other medication during the 
baseline period, providing assurance that medication use and medical interactions all would 
be observable in the billing claims database.
Exposure Information
The 30 days before colonoscopy were considered the exposure period (Figure 1), during 
which pharmacy claims were queried for dispensing of prescription OSP tablets or PEG 
bowel preparation solutions. We could observe only pharmacy-dispensed OSP use; over-the-
counter products would not appear in claims and thus were unavailable for analysis. 
Supplementary Table 1 lists the included OSP and PEG formulations of interest. It was 
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assumed that regardless of when the prescription was dispensed in the 30-day exposure 
window, it would be ingested on the day before or the day of the colonoscopy. Thus, the date 
of the colonoscopy was the beginning of the follow-up period. To restrict the analysis to new 
users of the medications, we excluded individuals with use of either agent in the baseline 
year before the exposure period. The drug exposure status at the index date was carried 
throughout the follow-up evaluation in an intent-to-treat analysis because we were interested 
in only one initial drug exposure.
Outcome Information
We followed individuals for 6 months for renal outcomes. We defined AKI as an inpatient or 
outpatient diagnosis code for acute renal failure (International Classification of Diseases, 9th 
revision, Clinical Modification codes 584.5–584.9). As sensitivity analyses, we used 
additional definitions of renal injury, as follows: (1) a procedure code for dialysis; (2) a 
diagnosis of AKI plus a procedure code for dialysis—the most restrictive although the most 
sensitive definition identifying the most extreme cases; (3) a composite definition of any 
kidney failure, which included International Classification of Diseases, 9th revision codes of 
AKI, unspecified kidney failure (586), end-stage renal disease (585.6), or a procedure code 
for dialysis, which was the most broad, inclusive definition.
Covariate Information
We defined covariates from submitted procedure claims, diagnoses, and medication 
dispensing, which occurred during the baseline year. Covariates included patient 
demographics, renal risk factors and other comorbid conditions, markers of health care use, 
prevalent medication use, and other medications initiated during the exposure period. Table 
1 shows a complete list of covariates. Supplementary Table 2 shows the definitions of our 
included covariates using administrative claims coding. Because of the nature of our claims-
based data, if a claim with a diagnosis or procedure was not submitted during the covariate 
assessment period, we considered the condition not present.
Statistical Analysis
We calculated adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) using 
multivariable Cox proportional hazards models. Follow-up time was censored at the first 
occurrence of the following: 6 months after the index date, plan un-enrollment, or the end of 
the study (May 10, 2009, which was 180 days after the last possible index date).
Propensity Score Matching
Analyses were repeated using propensity score (PS) matching. The predicted probability of 
initiating OSP vs PEG—the PS for treatment—was estimated with multivariable logistic 
regression from the measured covariates. We created an exchangeable comparison group of 
PEG users by 1:1 matching them to sodium phosphate users using a greedy matching 
algorithm that matches up to the fifth decimal of the PS, if possible, and excluding those 
who fail to match.27 Cox proportional hazards models then were run in the matched cohorts. 
In subgroup analyses, the PS was re-estimated, and the matching algorithm was run within 
each subgroup.
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To avoid bias caused by channeling of high-risk patients away from OSP in response to early 
reports of OSP-associated AKI, we performed a restricted analysis in colonoscopy patients 
before 2005, and then in 2005 to 2008.
Results
We identified 550,696 eligible participants undergoing outpatient colonoscopies, 429,430 of 
whom were prescribed PEG and 121,266 were prescribed OSP before the procedure. Table 1 
shows the characteristics of the study participants according to the choice of bowel 
purgative. There was a slight predominance of females in both groups, and the proportion of 
females was higher in the OSP group vs the PEG group. Individuals in the PEG group were 
slightly older than those in the OSP group and had a higher prevalence of comorbid 
conditions such as diabetes mellitus, chronic kidney disease (CKD), hypertension, and 
cardiovascular disease. The frequency of recent kidney stones and diagnoses of 
hypercalciuria were similar in the 2 groups. Prevalent medication use for a variety of agents 
was higher among the PEG group, including the frequency of angiotensin-converting 
enzyme inhibitors, angiotensin II receptor blockers, diuretics, and nonsteroidal anti-
inflammatory drugs. Medicines initiated during the exposure period for the 2 groups were 
comparable. We matched OSP to PEG users on the PS very successfully, and the distribution 
of covariates was much more similar between the 2 matched groups.
Patients were followed for up to 180 days for the outcome or censoring. Patients had a mean 
follow-up time of 170.7 days (SD, 32.0 d). There was a total of 1595 episodes of AKI in the 
cohort: 241 (0.2%) in the OSP group, and 1354 (0.3%) in the PEG group. Other outcomes, 
including any kidney failure or the need for dialysis, were distributed similarly between the 
2 groups.
The unadjusted HR of AKI for the OSP group compared with PEG was 0.63 (95% CI, 0.55–
0.72) (Table 2). After adjustment for potential confounders, the HR was attenuated to 0.86 
(95% CI, 0.75–0.99). Among the subgroups reported to have an increased risk of AKI, OSP 
use was not associated with an increased risk of AKI compared with PEG in the adjusted 
analyses. The clinically relevant subgroups included individuals with baseline CKD (HR, 
0.91; 95% CI, 0.58–1.42), advanced age (≥60 y) (HR, 0.83; 95% CI, 0.70–0.99), diabetes 
mellitus (HR, 0.77; 95% CI, 0.60–0.98), and the concurrent use of nonsteroidal anti-
inflammatory drugs (HR, 0.84; 95% CI, 0.65–1.08) or angiotensin-converting enzyme 
inhibitors/angiotensin II receptor blockers (HR, 0.89; 95% CI, 0.75–1.05). Among 
individuals with a history of hypercalciuria, the observed point estimate was increased (HR, 
2.80; 95% CI, 0.84–9.29), although the 95% CIs were wide from the small number of events 
in either treatment group; this association was not observed in any of the sensitivity analyses 
using other definitions of AKI (Supplementary Tables 3–5). As a whole, the sensitivity 
analyses for dialysis, any renal failure outcome, and AKI requiring dialysis agreed with the 
primary analysis very well. However, some subgroups suffered from a very small number of 
events per treatment group, leading to unstable estimates.
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Figure 2 shows the distribution of the PS for the 2 treatments in the overall population. The 
high degree of overlap for the majority of users of either agent suggests good 
exchangeability between the OSP and PEG users and low confounding by measured 
characteristics. The OSP treatment group matched the PEG users very well, with almost all 
(99.9%) OSP users being retained in all analyses. The distribution of covariates in the PS-
matched users is shown in Table 1; very good balance of covariates was achieved between 
the 2 matched treatments. The PS-matched HRs agreed very well with the adjusted 
estimates. The matched HR was 0.85 (95% CI, 0.72–1.01) for the entire group. All other 
matched subgroup estimates can be seen in Table 2.
When the sensitivity analyses were run in the years 2000 to 2004 and 2005 to 2008, there 
was virtually no change in adjusted estimates from the overall sample (2000–2004: HR, 
0.87; 95% CI, 0.64–1.19; and 2005–2008; HR, 0.86; 95% CI, 0.73–1.00), suggesting 
minimal channeling of high-risk patients to PEG in the later periods of the study.
Discussion
In this cohort study of nearly 555,000 middle-aged men and women undergoing outpatient 
colonoscopies, we examined the comparative risk of AKI associated with OSP vs PEG. We 
did not find a consistent increased risk of AKI associated with the use of OSP compared 
with PEG in the full cohort, in the PS-matched analysis, or in any subgroup such as 
individuals with CKD, advanced age, diabetes mellitus, or concurrent user of medications 
known to increase AKI risk. Rather, there appeared to be a consistent finding of null or 
slightly decreased risk of AKI associated with OSP vs PEG.
Previous studies regarding the risk of AKI after OSP cathartic use have shown mixed 
findings. A meta-analysis summarizing data from 7 studies with more than 13,000 patients 
reported inconclusive findings that could neither support or refute that OSP was associated 
with AKI.10 Our analysis had distinct advantages over these earlier studies. First, the design, 
which identified new users, anchored on an outpatient screening colonoscopy, and utilized 
well-defined exposure and follow-up periods, was meant to identify a cohort of patients 
equally likely to receive either OSP or PEG in a homogenous group of colonoscopy 
procedures. Second, the PS matching analysis showed a high degree of exchangeability 
between the 2 groups, evidenced both by the distribution of the covariates in the matched 
cohort and the large amount of overlap of the PS distributions; this allowed for a comparison 
of the 2 exposures with minimal confounding by measured characteristics. Third, the large 
granular data set allowed for robust adjustment for numerous clinical risk factors, measures 
of health care use, and concurrent medication use in a very large cohort of patients.
We had postulated that higher urine calcium excretion may identify a subset of individuals at 
higher risk for renal tubular injury from calcium phosphate precipitation. Although all 
patients receiving OSP are likely to have sudden and massive renal tubular excretion of 
phosphate, high urinary calcium excretion theoretically may place them at higher risk for 
developing deposition of calcium phosphate in the renal interstitium and distal tubules, the 
same location noted on pathologic examination from renal biopsy specimens from patients 
with AKI after OSP exposure.5–9 Furthermore, ambient conditions, such as high urine pH or 
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high osmolality, would strongly favor precipitation of luminal calcium and phosphate.28,29 
We did not see a consistent association of OSP with AKI among individuals with a diagnosis 
of hypercalciuria or nephrolithiasis, but the use of diagnosis codes to identify individuals 
with abnormal calcium excretion by the kidney is arguably insensitive, and a minority of 
individuals also may have had disease-associated hypercalciuria. Ultimately, we identified 
very few individuals with the condition; further investigation may be warranted in cohorts 
with larger numbers of patients with confirmed hypercalciuria.
The findings of the study should be interpreted in the context of important limitations. First, 
administrative claims for AKI outcomes may be insensitive.30,31 Serum creatinine–based 
estimates of glomerular filtration rate or urinary biomarkers have a better ability to assess 
early changes in renal function, whereas claims-based measures are better suited to detect 
established events with good specificity. Although having such measures may have 
increased the detection of kidney injury, the frequency of AKI in this study was not notably 
different from previous studies of community-acquired AKI.32–35 In addition, measures of 
relative effect, such as the reported HRs, still may be unbiased36,37 given the high specificity 
of billing codes for AKI30; thus, we reported relative, rather than absolute, measures of 
effect.
A second limitation was the low sensitivity of claims to estimate baseline levels of kidney 
function; we used diagnosis codes for CKD, and these diagnoses were very rare and did not 
vary substantially by treatment group. In this sample from the general population of middle-
aged and older adults undergoing screening colonoscopies, it is unlikely that glomerular 
filtration rate is widely and consistently monitored. If glomerular filtration rate is unknown 
to the prescribing physician, then treatment choice cannot be influenced by it or confound 
the outcome association. To avoid the potential for differential prescribing based on renal 
function, we restricted our sample to colonoscopies occurring before AKI warnings were 
placed on OSP because we were concerned that after warnings were made, patients at higher 
risk of AKI would be channeled toward PEG, confounding the treatment-AKI association. 
The result remained consistent even after further restriction of the time period from 2000 to 
2004, long before reports of OSP-induced AKI were widespread.
Third, our study used pharmacy dispensing claims to define exposure rather than direct 
measures of patients taking the medication. This prevented us from estimating the dose 
administered. Furthermore, we could only observe prescription medication use, not over-the-
counter sodium phosphate–containing kits, which patients may have used during the 
exposure period. Thus, there is the potential for exposure misclassification by over-the-
counter use. However, we would assume that because all our included patients had filled 
prescriptions for a bowel preparation agent, they would use the OSP or PEG in their 
possession, minimizing the risk of misclassification. Similarly to other studies, we could not 
assess the adequacy of patient hydration practices while using the medications.
In addition, as with any observational study, there is the possibility of residual confounding 
by unmeasured covariates. We adjusted for many covariates, and PS matching provided 
highly similar groups with a similar distribution of covariates. Yet, remaining differences in 
unmeasured potential confounders may have masked the true association of OSP with AKI.
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Finally, this study used US-based health care claims from individuals with employer-based 
commercial or Medicare supplementary insurance coverage, perhaps making the reported 
estimates less generalizable to uninsured populations, those with governmental insurance 
coverage, or other countries outside the United States.
In summary, this study did not show an increased AKI risk associated with OSP vs PEG in 
this large sample, generally representative of the insured, adult screening population. This 
result agrees with many previously published studies that have shown no difference between 
OSP and PEG15,17,20 or any non-OSP preparation agent.18 Nonetheless, calcium phosphate 
deposition and AKI have been shown by kidney biopsy in some individuals recently exposed 
to OSP. Even though these individual risks did not translate to a population risk in this study, 
future research should be directed toward understanding the occurrence of renal injury in 
specific individuals after OSP exposure.
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Cohort schematic of new users of OSP or PEG before colonoscopy.
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Propensity score distributions by precolonoscopy bowel preparation treatment.
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Table 1
Baseline Demographics and Outcomes by Statin Initiation Status










 Male, % 46.9 39.4 39.6 36.4
 Mean age, y (SD) 59.8 (7.1) 58.3 (6.4) 58.4 (6.4) 58.3 (6.4)
Renal risk factors
 Diabetes, % 15.9 12.5 12.4 12.5
 CKD, %   1.2   0.7   0.7   0.7
 Other kidney disease, %   0.3   0.2   0.2   0.2
 Proteinuria, %   0.4   0.3   0.4   0.3
 Kidney stones, %   1.9   1.8   1.8   1.8
 Hypercalciuria, %   0.4   0.5   0.4   0.5
 Mean number of creatinine measurements (SD) 0.01 (0.20) 0.01 (0.15) 0.01 (0.18) 0.01 (0.15)
CVD and comorbid conditions
 Hypertension, % 39.6 36.3 36.1 36.3
 Hyperlipidemia, % 29.8 39.2 38.7 39.2
 Other ischemic heart disease, % 10.7   7.9   7.8   7.9
 Atrial fibrillation, %   2.4   1.5   1.6   1.5
 Heart failure, %   1.9   1.0   1.1   1.0
 Chronic liver disease and cirrhosis, %   2.9   2.6   2.6   2.6
 Multiple myeloma, %   0.1   0.1   0.1   0.1
 Systemic lupus erythematosus, %   0.7   0.7   0.7   0.7
 Metabolic disorders, %   1.0   0.9   0.9   0.9
Prevalent medication use during baseline
 Statins, % 36.4 33.8 33.9 33.8
 ACE inhibitors, % 23.1 19.0 19.1 19.0
 ARBs, % 13.7 13.3 13.3 13.3
 β-blockers, % 22.1 18.2 18.2 18.2
 Calcium channel blockers, % 16.0 13.3 13.0 13.3
 Antiplatelet agents, %   4.7   3.6   3.5   3.6
 α-blockers, %   4.3   2.9   3.0   2.9
 Thiazides, % 24.6 22.8 22.9 22.8
 Potassium-sparing diuretics, %   6.8   6.2   6.1   6.2
 Loop diuretics, %   5.6   4.0   3.9   4.0
 Niacin, %   2.0   1.9   1.8   1.9
 Fibrates, %   4.3   3.9   3.9   3.9
 Ezetimibe, %   6.4   6.8   6.7   6.8
 Anticoagulants, %   3.4   2.2   2.2   2.2
 NSAIDs, % 26.3 26.2 25.9 26.2
Medications initiated during exposure window
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 Statins, %   1.3   1.4   1.4   1.4
 ACE inhibitors, %   0.7   0.6   0.6   0.6
 ARBs, %   0.4   0.4   0.4   0.4
 β-blockers, %   0.5   0.4   0.4   0.4
 Calcium channel blockers, %   0.4   0.3   0.3   0.3
 Antiplatelet agents, %   0.1   0.1   0.1   0.1
 α-blockers, %   0.1   0.1   0.1   0.1
 Thiazides, %   0.7   0.7   0.7   0.7
 Potassium-sparing diuretics, %   0.2   0.2   0.2   0.2
 Loop diuretics, %   0.2   0.2   0.2   0.2
 Niacin, %   0.1   0.1   0.1   0.1
 Fibrates, %   0.2   0.2   0.2   0.2
 Ezetimibe, %   0.4   0.4   0.4   0.4
 Anticoagulants, %   0.1   0.0   0.0   0.0
 NSAIDs, %   1.2   1.3   1.2   1.3
ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; CVD, cardiovascular disease; NSAIDs, nonsteroidal anti-inflammatory 
drugs.
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